Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Gilteritinib Fumarate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 49,100Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Astellas To Unveil XOSPATA Data On FLT3M+ AML At ASH 2025 Meeting
    Astellas To Unveil XOSPATA Data On FLT3M+ AML At ASH 2025 Meeting

    05 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/astellas-to-present-new-data-on-xospata-gilteritinib-across-the-flt3m-aml-disease-continuum-at-ash-2025-annual-meeting-302633927.html

    PR NEWSWIRE
    05 Dec 2025
    Share Share
    Gilteritinib as Maintenance Therapy Shows Benefit in Subgroups of FLT3-ITD
    Gilteritinib as Maintenance Therapy Shows Benefit in Subgroups of FLT3-ITD

    09 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gilteritinib-as-maintenance-therapy-demonstrated-benefit-in-subgroups-of-flt3-itd-acute-myeloid-leukemia-patients-301846826.html

    PR NEWSWIRE
    09 Jun 2023
    Share Share
    Astellas Xospata comes up short again in bid to expand leukemia use
    Astellas Xospata comes up short again in bid to expand leukemia use

    10 Mar 2023

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/astellas-xospata-comes-short-again-bid-expand-label

    Kevin Dunleavy FIERCE PHARMA
    10 Mar 2023
    Share Share
    Astellas and BMT CTN Announce Results from PIII MORPHO Trial of Gilteritinib
    Astellas and BMT CTN Announce Results from PIII MORPHO Trial of Gilteritinib

    09 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/astellas-and-bmt-ctn-announce-topline-results-from-phase-3-morpho-trial-of-gilteritinib-301767481.html

    PR NEWSWIRE
    09 Mar 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Gilteritinib Fumarate Tablets
    FDA Confirms Paragraph IV Patent Litigation for Gilteritinib Fumarate Tablets

    13 Feb 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-gilteritinib-fumarate-tablets-13638.pdf

    FDA
    13 Feb 2023
    Share Share
    Kronos Begins Dosing in PIb/II Trial of Lanraplenib with Gilteritinib
    Kronos Begins Dosing in PIb/II Trial of Lanraplenib with Gilteritinib

    22 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/22/2502156/0/en/Kronos-Bio-Announces-First-Patient-Dosed-in-Phase-1b-2-Clinical-Trial-of-Lanraplenib-in-Combination-with-Gilteritinib-in-Acute-Myeloid-Leukemia.html

    GLOBENEWSWIRE
    22 Aug 2022
    Share Share